Pretreatment with Notoginsenoside R1 enhances the efficacy of neonatal rat mesenchymal stem cell transplantation in model of myocardial infarction through regulating PI3K/Akt/FoxO1 signaling pathways.

Autor: Cai H; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Han XJ; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Luo ZR; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Wang QL; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Lu PP; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Mou FF; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Zhao ZN; Development and Planning Division (Department of Discipline Development）, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. zhaozhinan25@163.com., Hu D; Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China. tiankon9598@163.com., Guo HD; Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. hdguo@shutcm.edu.cn.
Jazyk: angličtina
Zdroj: Stem cell research & therapy [Stem Cell Res Ther] 2024 Nov 13; Vol. 15 (1), pp. 419. Date of Electronic Publication: 2024 Nov 13.
DOI: 10.1186/s13287-024-04039-x
Abstrakt: Background: Although stem cell transplantation is a promising approach for the treatment of myocardial infarction (MI), there are still some problems faced such as the low survival rate of stem cells. Here, we investigated the role of Notoginsenoside R1 (NGR1) pretreatment in improving the effects of neonatal rat bone marrow mesenchymal stem cell (MSC) transplantation for treatment of MI.
Methods: Cardiac functions were detected by echocardiography and the myocardial infarct size was determined by Masson's trichrome staining in a rat model of MI. The cardioprotective effects of NGR1/LY294002 co-pretreated MSCs was evaluated to explore the underlying mechanism. The angiogenesis was determined by vWF and α-SMA immunofluorescence staining and cell apoptosis was detected by TUNEL. In vitro, the effects of NGR1 on stem cell proliferation was examined by CCK-8 and levels of P-Akt, P-CREB, P-FoxO1 were detected by western blot. Apoptosis, ROS content, and cytokine levels were examined by DAPI and TUNEL staining, a ROS assay kit, and ELISA, respectively.
Results: NGR1 elevated the therapeutic effect of MSC transplantation on infarction by preserving cardiac function, increasing angiogenesis and expressions of IGF-1, VEGF, and SDF-1, and reducing cell apoptosis, whereas the addition of LY294002 prior to NGR1 treatment significantly counteracted the foregoing effects of NGR1. NGR1 pretreatment and SC79 pretreatment were similar in that both significantly increased P-Akt and P-FoxO1 levels in MSC and did not affect P-CREB levels. Besides, both NGR1 and SC79 promoted VEGF, SCF and bFGF levels in MSC cultures, and significantly reduced ROS accumulation and the attenuated cell apoptosis in MSC triggered by H 2 O 2 . Similarly, addition of LY294002 before NGR1 treatment significantly counteracted the aforementioned effects of NGR1 in vitro.
Conclusions: NGR1 pretreatment enhances the effect of MSC transplantation for treatment of MI through paracrine signaling, and the mechanism underlying this effect may be associated with PI3K/Akt/FoxO1 signaling pathways.
Competing Interests: Declarations Ethics approval and consent to participate This study was approved by the Animal Ethics Committee of Shanghai University of TCM (No. PZSHUTCM190628003, approved on June 30, 2019). The title of the approved project was ‘Mechanism of optimizing microenvironment in induced pluripotent stem cell transplantation for myocardial infarction by qi replenishing and blood activating traditional Chinese medicine’. Consent for publication Not applicable. Competing interests The authors declare that they have no conflicts of interest.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje